Clear All
11888 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
63459-0910-01 63459-0910 tbo-filgrastim Granix 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Nov 11, 2013 In Use
63459-0918-59 63459-0918 tbo-filgrastim GRANIX 300.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Nov 7, 2018 In Use
63459-0910-17 63459-0910 tbo-filgrastim Granix 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Mar 2, 2015 In Use
63459-0912-15 63459-0912 tbo-filgrastim Granix 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Nov 11, 2013 In Use
63459-0912-01 63459-0912 tbo-filgrastim Granix 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Nov 11, 2013 In Use
63459-0910-11 63459-0910 tbo-filgrastim Granix 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Nov 11, 2013 In Use
63459-0912-12 63459-0912 tbo-filgrastim Granix 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Nov 11, 2013 In Use
63459-0912-36 63459-0912 tbo-filgrastim Granix 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Mar 2, 2015 In Use
80446-0401-01 80446-0401 TEBENTAFUSP KIMMTRAK 100.0 ug/.5mL Immunotherapy T Cell Receptor (TCR) HLA-A*02:01 Intravenous Jan 26, 2022 In Use
57894-0450-01 57894-0450 Teclistamab TECVAYLI 90.0 mg/mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Oct 25, 2022 In Use
57894-0449-01 57894-0449 Teclistamab TECVAYLI 10.0 mg/mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Oct 25, 2022 In Use
00074-1055-01 00074-1055 Telisotuzumab Vedotin EMRELIS 100.0 mg/mL Immunotherapy Drug Antibody Conjugate c-MET Intravenous May 14, 2025 In Use
00074-1044-01 00074-1044 Telisotuzumab Vedotin EMRELIS 20.0 mg/mL Immunotherapy Drug Antibody Conjugate c-MET Intravenous May 14, 2025 In Use
50268-0763-11 50268-0763 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Mar 23, 2017 Jul 31, 2021 In Use
16571-0821-51 16571-0821 Temozolomide TEMOZOLOMIDE 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct 4, 2022 In Use
42737-0102-05 42737-0102 temozolomide TEMOZOLOMIDE 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec 31, 2018 Jan 24, 2019 In Use
40051-0605-11 40051-0605 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug 1, 2016 In Use
00378-5264-14 00378-5264 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Jun 29, 2016 Feb 28, 2018 No Longer Used
42737-0102-14 42737-0102 temozolomide TEMOZOLOMIDE 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec 31, 2018 Jan 24, 2019 In Use
40051-0604-12 40051-0604 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug 1, 2016 In Use
50268-0761-12 50268-0761 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Mar 23, 2017 In Use
00085-1519-01 00085-1519 Temozolomide Temodar 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug 11, 1999 Oct 22, 2014 In Use
54868-4142-00 54868-4142 Temozolomide Temodar 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Jun 29, 2005 In Use
31722-0412-31 31722-0412 TEMOZOLOMIDE TEMOZOLOMIDE 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug 23, 2024 In Use
00527-1782-55 00527-1782 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Mar 23, 2016 May 24, 2018 In Use

Found 11888 results — Export these results